Three years ago, technology startup Biofourmis had raised $10 million in total funding. This week, the virtual care and digital medicine-focused company announced a massive $300 million cash injection to fuel its growth.
The funding round has boosted Biofourmis’ valuation to more than $1 billion, according to executives.
The series D investment was led by leading global growth equity firm General Atlantic. CVS Health and existing investors also participated in the round.
